» Articles » PMID: 38704482

Exploring the Mechanism of Jinlida Granules Against Type 2 Diabetes Mellitus by an Integrative Pharmacology Strategy

Overview
Journal Sci Rep
Specialty Science
Date 2024 May 4
PMID 38704482
Authors
Affiliations
Soon will be listed here.
Abstract

Jinlida granule (JLD) is a Traditional Chinese Medicine (TCM) formula used for the treatment of type 2 diabetes mellitus (T2DM). However, the mechanism of JLD treatment for T2DM is not fully revealed. In this study, we explored the mechanism of JLD against T2DM by an integrative pharmacology strategy. Active components and corresponding targets were retrieved from Traditional Chinese Medicine System Pharmacology (TCMSP), SwissADME and Bioinformatics Analysis Tool for Molecular Mechanisms of Traditional Chinese Medicine Database (BATMAN-TCM) database. T2DM-related targets were obtained from Drugbank and Genecards databases. The protein-protein interaction (PPI) network was constructed and analyzed with STRING (Search Toll for the Retrieval of Interacting Genes/proteins) and Cytoscape to get the key targets. Then, Gene Ontology (GO) and Kyoto Encyclopedia of Gene and Genomes (KEGG) enrichment analyses were performed with the Database for Annotation, Visualization and Integrated Discovery (DAVID). Lastly, the binding capacities and reliability between potential active components and the targets were verified with molecular docking and molecular dynamics simulation. In total, 185 active components and 337 targets of JLD were obtained. 317 targets overlapped with T2DM-related targets. RAC-alpha serine/threonine-protein kinase (AKT1), tumor necrosis factor (TNF), interleukin-6 (IL-6), cellular tumor antigen p53 (TP53), prostaglandin G/H synthase 2 (PTGS2), Caspase-3 (CASP3) and signal transducer and activator of transcription 3 (STAT3) were identified as seven key targets by the topological analysis of the PPI network. GO and KEGG enrichment analyses showed that the effects were primarily associated with gene expression, signal transduction, apoptosis and inflammation. The pathways were mainly enriched in PI3K-AKT signaling pathway and AGE-RAGE signaling pathway in diabetic complications. Molecular docking and molecular dynamics simulation verified the good binding affinity between the key components and targets. The predicted results may provide a theoretical basis for drug screening of JLD and a new insight for the therapeutic effect of JLD on T2DM.

Citing Articles

5,7-Dihydroxyflavone acts on eNOS to achieve hypotensive effects in spontaneously hypertensive rats.

Shen Z, Ye T, Chen B, Wan C, Lu X, Chen T Sci Rep. 2025; 15(1):594.

PMID: 39747252 PMC: 11695686. DOI: 10.1038/s41598-024-84259-6.


Jinlida granules alleviate podocyte apoptosis and mitochondrial dysfunction via the AMPK/PGC‑1α pathway in diabetic nephropathy.

Sun S, Yang S, Cheng Y, Fang T, Qu J, Tian L Int J Mol Med. 2024; 55(2).

PMID: 39670303 PMC: 11670860. DOI: 10.3892/ijmm.2024.5467.


Analysis of type 2 diabetes mellitus-related genes by constructing the pathway-based weighted network.

Zhang X, Xu C, Cao K, Luo H, Zhang X IET Syst Biol. 2024; 19(1):e12110.

PMID: 39661495 PMC: 11821747. DOI: 10.1049/syb2.12110.


Mechanism of action of Salvia miltiorrhiza on avascular necrosis of the femoral head determined by integrated network pharmacology and molecular dynamics simulation.

Wang X, Wu L, Luo D, He L, Wang H, Peng B Sci Rep. 2024; 14(1):28479.

PMID: 39558045 PMC: 11574184. DOI: 10.1038/s41598-024-79532-7.

References
1.
Lontchi-Yimagou E, Sobngwi E, Matsha T, Kengne A . Diabetes mellitus and inflammation. Curr Diab Rep. 2013; 13(3):435-44. DOI: 10.1007/s11892-013-0375-y. View

2.
Yuan F, Zhang M, Xu P, Xu D, Chen P, Ren M . Tanshinone IIA improves diabetes mellitus via the NF-κB-induced AMPK signal pathway. Exp Ther Med. 2018; 16(5):4225-4231. PMC: 6176167. DOI: 10.3892/etm.2018.6674. View

3.
Li Y, Tang Y, Shi S, Gao S, Wang Y, Xiao D . Tetrahedral Framework Nucleic Acids Ameliorate Insulin Resistance in Type 2 Diabetes Mellitus the PI3K/Akt Pathway. ACS Appl Mater Interfaces. 2021; 13(34):40354-40364. DOI: 10.1021/acsami.1c11468. View

4.
Adeshara K, Diwan A, Tupe R . Diabetes and Complications: Cellular Signaling Pathways, Current Understanding and Targeted Therapies. Curr Drug Targets. 2015; 17(11):1309-28. DOI: 10.2174/1389450117666151209124007. View

5.
Afroz A, Alramadan M, Hossain M, Romero L, Alam K, Magliano D . Cost-of-illness of type 2 diabetes mellitus in low and lower-middle income countries: a systematic review. BMC Health Serv Res. 2018; 18(1):972. PMC: 6296053. DOI: 10.1186/s12913-018-3772-8. View